Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Mar;73(6):770–775. doi: 10.1038/bjc.1996.134

Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.

B Wangberg 1, E Forssell-Aronsson 1, L E Tisell 1, O Nilsson 1, M Fjalling 1, H Ahlman 1
PMCID: PMC2074371  PMID: 8611378

Abstract

After injection of 111In-labelled DTPA-D-Phe1-octreotide, intraoperative tumour localisation was performed using a scintillation detector in 23 patients with neuroendocrine tumours. Count rates from suspect tumour lesions and adjacent normal tissue were expressed as a ratio before (Rin situ) and after (Rex vivo) excision. 111In activity concentration ratios of tumour tissue to blood (T/B) were determined in a gamma counter. In patients with midgut carcinoids, (all scintigraphy positive), false Rin situ recordings were found in 4/29 macroscopically identified tumours. T/B ratios were all high (27-650). In patients with medullary thyroid carcinomas (eight out of ten scintigraphy positive), misleading Rin situ results were found in 4/37 macroscopically identified tumours. T/B ratios were lower (3-39) than those seen in midgut carcinoids. Two out of four patients with endocrine pancreatic tumours had positive scintigraphy, reliable intraoperative measurements and very high T/B ratios (910-1500). One patient with a gastric carcinoid had correct measurements in situ and ex vivo with high T/B ratios (71-210). In situ measurements added little information to preoperative scintigraphy and surgical findings using the present detection system. Rex vivo measurements were more reliable. The very high T/B ratios seen in midgut carcinoids and some endocrine pancreatic tumours would be favourable for future radiation therapy via somatostatin receptors.

Full text

PDF
771

Images in this article

772Figure 1
on p.772
773Figure 2
on p.773
774Figure 3
on p.774

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlman H., Wängberg B., Tisell L. E., Nilsson O., Fjälling M., Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg. 1994 Aug;81(8):1144–1149. doi: 10.1002/bjs.1800810820. [DOI] [PubMed] [Google Scholar]
  2. Bakker W. H., Krenning E. P., Reubi J. C., Breeman W. A., Setyono-Han B., de Jong M., Kooij P. P., Bruns C., van Hagen P. M., Marbach P. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci. 1991;49(22):1593–1601. doi: 10.1016/0024-3205(91)90053-e. [DOI] [PubMed] [Google Scholar]
  3. Bruns C., Weckbecker G., Raulf F., Kaupmann K., Schoeffter P., Hoyer D., Lübbert H. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci. 1994 Sep 15;733:138–146. doi: 10.1111/j.1749-6632.1994.tb17263.x. [DOI] [PubMed] [Google Scholar]
  4. Curtet C., Vuillez J. P., Daniel G., Aillet G., Chetanneau A., Visset J., Kremer M., Thédrez P., Chatal J. F. Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody. Eur J Nucl Med. 1990;17(6-8):299–304. doi: 10.1007/BF01268019. [DOI] [PubMed] [Google Scholar]
  5. Forssell-Aronsson E., Fjälling M., Nilsson O., Tisell L. E., Wängberg B., Ahlman H. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl Med. 1995 Jan;36(1):7–12. [PubMed] [Google Scholar]
  6. Krenning E. P., Bakker W. H., Kooij P. P., Breeman W. A., Oei H. Y., de Jong M., Reubi J. C., Visser T. J., Bruns C., Kwekkeboom D. J. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992 May;33(5):652–658. [PubMed] [Google Scholar]
  7. Krenning E. P., Kwekkeboom D. J., Bakker W. H., Breeman W. A., Kooij P. P., Oei H. Y., van Hagen M., Postema P. T., de Jong M., Reubi J. C. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993 Aug;20(8):716–731. doi: 10.1007/BF00181765. [DOI] [PubMed] [Google Scholar]
  8. Lamberts S. W., Bakker W. H., Reubi J. C., Krenning E. P. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990 Nov 1;323(18):1246–1249. doi: 10.1056/NEJM199011013231805. [DOI] [PubMed] [Google Scholar]
  9. Pedley R. B., Boden J., Keep P. A., Harwood P. J., Green A. J., Rogers G. T. Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft. Eur J Nucl Med. 1987;13(4):197–202. doi: 10.1007/BF00256491. [DOI] [PubMed] [Google Scholar]
  10. Reubi J. C., Chayvialle J. A., Franc B., Cohen R., Calmettes C., Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991 Apr;64(4):567–573. [PubMed] [Google Scholar]
  11. Reubi J. C., Krenning E., Lamberts S. W., Kvols L. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1073–1077. doi: 10.1016/0960-0760(90)90468-z. [DOI] [PubMed] [Google Scholar]
  12. Reubi J. C., Maurer R., von Werder K., Torhorst J., Klijn J. G., Lamberts S. W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987 Jan 15;47(2):551–558. [PubMed] [Google Scholar]
  13. Sardi A., Workman M., Mojzisik C., Hinkle G., Nieroda C., Martin E. W., Jr Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system). Arch Surg. 1989 Jan;124(1):55–59. doi: 10.1001/archsurg.1989.01410010065014. [DOI] [PubMed] [Google Scholar]
  14. Schirmer W. J., O'Dorisio T. M., Schirmer T. P., Mojzisik C. M., Hinkle G. H., Martin E. W. Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surgery. 1993 Oct;114(4):745–752. [PubMed] [Google Scholar]
  15. Tisell L. E., Hansson G., Jansson S., Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986 Jan;99(1):60–66. [PubMed] [Google Scholar]
  16. Waddington W. A., Kettle A. G., Heddle R. M., Coakley A. J. Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med. 1994 Apr;21(4):363–364. doi: 10.1007/BF00947974. [DOI] [PubMed] [Google Scholar]
  17. Williams L. E., Duda R. B., Proffitt R. T., Beatty B. G., Beatty J. D., Wong J. Y., Shively J. E., Paxton R. J. Tumor uptake as a function of tumor mass: a mathematic model. J Nucl Med. 1988 Jan;29(1):103–109. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES